The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases
Abstract
BACKGROUND AND AIMS: Treatment goals in inflammatory bowel diseases are evolving beyond the control of symptoms towards the tight control of objectively-measured gastrointestinal inflammation. This review discusses the progress and challenges in adopting a treat-to-target approach in inflammatory bowel diseases. METHODS: Evidence from the literature that highlights current thinking in terms of treating-to-target in patients with inflammatory bowel diseases is discussed. RESULTS: Monitoring for objective evidence of inflammation using endoscopy, cross-sectional imaging or laboratory biomarkers may be a useful approach in inflammatory bowel diseases; however, setting the appropriate treatment goal remains a challenge. Deep remission (a composite of symptom control and mucosal healing) may now be a realistic target in Crohn's disease; however, it remains to be proven that achieving deep remission will modify the long-term disease course. Assessing prognosis at an early stage of the disease course is essential for the development of an appropriate management plan, with the rationale of adapting treatment to disease severity. An algorithm has been proposed for the treatment of early Crohn's disease that involves early treatment with immunosuppressants and tumour necrosis factor antagonists, in the hope of preventing structural bowel damage. CONCLUSIONS: Treating beyond symptoms will require a clear management plan influenced by disease severity at presentation, clinical and biological prognostic factors, achievement and maintenance of clinical and biological remission and pharmacoeconomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f0580f · Cited by 1,837
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Cellier, C., Sahmoud, T., Froguel, E., Adenis, A., Belaiche, J., Bretagne, J. F., Florent, C., Bouvry, M., Mary, J. Y., & Modigliani, R. (1994) · Gut · doi:10.1136/gut.35.2.231 · Cited by 430
Lee, J. C., Lyons, P. A., McKinney, E. F., Sowerby, J. M., Carr, E. J., Bredin, F., Rickman, H. M., Ratlamwala, H., Hatton, A., Rayner, T. F., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59255 · Cited by 304
Cited by
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Dolinger, M., Torres, J., & Vermeire, S. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02586-2 · Cited by 580
Metadata
- Authors
- Sandborn, W. J., Hanauer, S., Van Assche, G., Panés, J., Wilson, S., Petersson, J., & Panaccione, R.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-09-01
- Volume
- 8
- Issue
- 9
- Pages
- 927-935
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2046898743
- Cited by
- 158
- References
- 6
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.